James W. Lynch

1.4k total citations
34 papers, 1.1k citations indexed

About

James W. Lynch is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, James W. Lynch has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pathology and Forensic Medicine, 15 papers in Oncology and 9 papers in Neurology. Recurrent topics in James W. Lynch's work include Lymphoma Diagnosis and Treatment (21 papers), CNS Lymphoma Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). James W. Lynch is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), CNS Lymphoma Diagnosis and Treatment (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). James W. Lynch collaborates with scholars based in United States, Canada and Sweden. James W. Lynch's co-authors include Nancy P. Mendenhall, Lucio Gordan, C. Varns, Lawrence D. Piro, Vinay Jain, Christine A. White, T Beck, Alan Saven, Steve Shuey and M. S. Czuczman and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

James W. Lynch

33 papers receiving 1.0k citations

Peers

Countries citing papers authored by James W. Lynch

Since Specialization

Citations

This map shows the geographic impact of James W. Lynch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. Lynch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. Lynch more than expected).

Fields of papers citing papers by James W. Lynch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James W. Lynch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. Lynch. The network helps show where James W. Lynch may publish in the future.

Co-authorship network of co-authors of James W. Lynch

This figure shows the co-authorship network connecting the top 25 collaborators of James W. Lynch. A scholar is included among the top collaborators of James W. Lynch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James W. Lynch. James W. Lynch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma 2021 ·International Journal of Radiation OncologyBiologyPhysics ·Raymond B. Mailhot Vega, Homan Mohammadi, Samir Patel, Adam L. Holtzman, Natalie A. Lockney, James W. Lynch, (unknown), Xiaoying Liang, William B. Slayton, Susan K. Parsons, Bradford S. Hoppe, Nancy P. Mendenhall	9
2	How Bureaucracy Can Foster Burnout 2018 ·Journal of the American College of Radiology ·Richard B. Gunderman, James W. Lynch	3
3	Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Bradford S. Hoppe, Stella Flampouri, (unknown), William B. Slayton, Eric Sandler, (unknown), Nam H. Dang, James W. Lynch, Zuofeng Li, Christopher G. Morris, Nancy P. Mendenhall	48
4	Outcomes of Patients with Non-Hodgkin's Lymphoma Treated with Bexxar With or Without External-Beam Radiotherapy 2010 ·International Journal of Radiation OncologyBiologyPhysics ·Kristy Smith, (unknown), Christopher G. Morris, Jessica Kirwan, (unknown), Nancy P. Mendenhall, Bradford S. Hoppe, James W. Lynch, Kenneth R. Olivier	1
5	Long-term Outcomes for Stage I–II Aggressive Non-Hodgkin Lymphoma of Waldeyer's Ring 2009 ·American Journal of Clinical Oncology ·Daniel T. Chang, Nancy P. Mendenhall, James W. Lynch, Christopher G. Morris, Kenneth R. Olivier	10
6	Lethal Midline Granuloma-Nasal Natural Killer/T-Cell Lymphoma 2006 ·American Journal of Clinical Oncology ·William M. Mendenhall, Kenneth R. Olivier, James W. Lynch, Nancy P. Mendenhall	18
7	A Phase II Study of Gemcitabine in Patients With Relapsed or Refractory Low-Grade Non-Hodgkin Lymphoma 2005 ·American Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Nancy P. Mendenhall, James W. Lynch	6
8	Paraneoplastic Manifestations of Lymphoma 2004 ·Clinical Lymphoma ·(unknown), James W. Lynch	39
9	Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation 2003 ·Leukemia & lymphoma ·Lucio Gordan, Michele W. Sugrue, James W. Lynch, (unknown), Shahab Khan, John R. Wingard, Jan S. Moreb	79
10	Management of neurotropic low‐grade B‐cell lymphoma: Report of two cases 2003 ·Head & Neck ·(unknown), Nancy P. Mendenhall, Russell W. Hinerman, James W. Lynch, Raul C. Braylan, Anthony Mancuso	12
11	Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma 2003 ·Bone Marrow Transplantation ·Lucio Gordan, Michele W. Sugrue, James W. Lynch, (unknown), Shahab Khan, Jan S. Moreb	67
12	Phase II Study of Fludarabine Combined With Interferon-α-2a Followed by Maintenance Therapy With Interferon-α-2a in Patients With Low-Grade Non-Hodgkin’s Lymphoma 2002 ·American Journal of Clinical Oncology ·James W. Lynch, (unknown), Raul C. Braylan, (unknown), Edward V. Staab, (unknown), Nancy P. Mendenhall, (unknown)	7
13	Dose-Intense Ifosfamide/Doxorubicin/Cisplatin Based Chemotherapy for Osteosarcoma in Adults 2002 ·American Journal of Clinical Oncology ·Shailesh J. Patel, James W. Lynch, Tom Johnson, Robert R. Carroll, (unknown), (unknown), Mark T. Scarborough	35
14	Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma 1999 ·Annals of Oncology ·Lawrence D. Piro, Christine A. White, A.J. Grillo-López, Nalini Janakiraman, Alan Saven, T Beck, C. Varns, Steve Shuey, M. S. Czuczman, James W. Lynch, (unknown), Vinay Jain	308
15	Non-Hodgkin's lymphoma of the head and neck: A 30-year experience at the university of Florida 1999 ·Head & Neck ·(unknown), Nancy P. Mendenhall, Nidal M. Almasri, James W. Lynch	45
16	Is comprehensive lymphatic irradiation for low-grade non-Hodgkin's lymphoma curative therapy? long-term experience at a single institution 1997 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Nancy P. Mendenhall, James W. Lynch	23
17	Toward a Rational Approach to Systemic Therapy in Local Recurrence of Breast Cancer 1996 ·The Breast Journal ·James W. Lynch, Robert Marsh	1
18	Stevens-Johnson Syndrome Resulting from Whole-Brain Radiation and Phenytoin 1996 ·American Journal of Clinical Oncology ·(unknown), Stephen T. Amann, (unknown), James W. Lynch	33
19	The Role of Prognostic Factors in Treatment Selection for Early-Stage Hodgkinʼs Disease 1994 ·American Journal of Clinical Oncology ·Nancy P. Mendenhall, Alan Cantor, (unknown), James W. Lynch, Rodney R. Million	21
20	Cisplatin chemotherapy for basal cell carcinoma: The need for posttreatment biopsy—report of a case 1990 ·Journal of the American Academy of Dermatology ·(unknown), (unknown), (unknown), James W. Lynch	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact